Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Radboud University Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02968303CT.gov Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Clear Cell Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cobimetinib (this asset) | Radboud University Medical Center | P2 | CCC · 53 |
| Tivantinib | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | P2 | B |
| Crizotinib | European Organisation for Research and Treatment of Cancer - EORTC | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Vemurafenib | Radboud University Medical Center | P2 | CCC |
| Zoledronate | University of Florida | P1/2 | CCC |
| Cyclophosphamide | St. Jude Children's Research Hospital | P1 | CC |
| Sirolimus | Emory University | P1 | CC |
+11 more in the Clear Cell Sarcoma cohort
Other indications for Cobimetinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | B · 62 |
| Melanoma | — | P3 | B · 62 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2/3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- TivantinibArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)B
- CrizotinibEuropean Organisation for Research and Treatment of Cancer - EORTCB
- CabozantinibNational Cancer Institute (NCI)CCC
- AtezolizumabNational Cancer Institute (NCI)CCC
- VemurafenibRadboud University Medical CenterCCC
Citation
Floatz Terminal. Cobimetinib in Clear Cell Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cobimetinib-clear-cell-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →